Company news

Connect Biopharma Holdings Limited news in 2022

Connect Biopharma Holdings Limited's news releases, calls and decks from 2022, newest first.

View company

Connect Biopharma Provides Business and Clinical Development Program Update

December 29, 2022

Connect Biopharma Announces Receipt of NASDAQ Deficiency Notice Regarding Minimum Bid Price Requirement

December 1, 2022

Connect Biopharma Reports CBP-201 Achieved All Primary and Key Secondary Endpoints in Pivotal Atopic Dermatitis (AD) Trial in China

October 3, 2022

Connect Biopharma to Host a Conference Call Tuesday, October 4 to Discuss Topline Results for the Pivotal Trial in China of Lead Candidate, CBP-201, in Patients with Moderate-to-Severe Atopic Dermatitis

October 2, 2022

Connect Biopharma Reports First Half 2022 Financial Results and Provides Business Update

September 12, 2022

Connect Biopharma to Report First Half 2022 Financial Results on September 13

August 31, 2022

Connect BioPharma Successfully Completes CBP-174 Phase 1 Single Ascending Dose Study

August 29, 2022

Connect Moves Forward CBP-201 Top-Line Results Timeline for Pivotal China Atopic Dermatitis Trial to Second Half 2022

July 10, 2022

Connect Biopharma Announces Week 12 Top-Line Results from Phase 2 CBP-307 Trial in Patients with Moderate-to-Severe Ulcerative Colitis

May 2, 2022

Connect Biopharma Reports Full Year 2021 Financial Results and Provides Business Update

March 30, 2022

Connect Biopharma Appoints Autoimmune and Immunology Expert Chin Lee, MD, MPH as Chief Medical Officer

February 28, 2022

Connect Biopharma Reports Detailed Positive Dataset from the Global Phase 2b Trial of CBP-201 in Adult Patients with Moderate-to-Severe Atopic Dermatitis

January 4, 2022

Connect Biopharma to Host Conference Call on January 5 at 8: 30 AM ET to Review Detailed Data from the Global Phase 2b Trial of CBP-201

January 3, 2022

Decks in 2022